Table 1Included interventions

DrugTrade nameLabeled indicationsDosing
Aspirin/extended-release dipyridamole 25 mg/200 mgAggrenox®To reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosisOne capsule bid
  • NSTEMI, including patients managed medically and those managed with coronary revascularization
Recent MI, recent stroke or established PAD
To reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death
NSTEMI: 300 mg loading dose, continue at 75 mg qd in combination with ASA 75 to 325 mg qd
STEMI: 75 mg qd in combination with 75–325 mg ASA with or without thrombolytics; Plavix® may be initiated with or without a loading dose
Recent MI, recent stroke or established PAD
75 mg qd
CYP2C19 Poor Metabolizers
Appropriate dose regimen has not been established
Use with PPI
An appropriate dosing regimen has not yet been established
PrasugrelEffientTo reduce the rate of thrombotic cardiovascular events in patients with ACS, managed with percutaneous coronary intervention as follows:
  • Patients with unstable angina or NSTEMI
  • Patients with STEMI when managed with primary or delayed percutaneous coronary intervention
60 mg loading dose then 10 mg qd; patients taking Effient should also take ASA 75–325 mg; patients <60 kg should lower maintenance dose to 5 mg
TiclopidineaGeneric onlyTo reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke
Adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation
250 mg bid
Coronary artery stenting
250 mg bid with ASA for 30 days of therapy following stent implantation

As monotherapy or in combination with aspirin.

Abbreviations: ACS, acute coronary syndrome; ASA, Aspirin; bid, twice daily; bid, twice daily; MI, myocardial infarction; NSTEMI, non-ST Segment Elevation Myocardial Infarction, PAD, peripheral arterial disease; PPI, proton pump inhibitor; qd, once daily; STEMI, ST Segment Elevation Myocardial Infarction.

From: Introduction

Cover of Drug Class Review: Newer Antiplatelet Agents
Drug Class Review: Newer Antiplatelet Agents: Final Update 2 Report [Internet].
Ketchum K, Peterson K, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2011 Jun.
Copyright © 2011 by Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.